Informa Partnership Adds Biopharma Modelling Tool

Business Intelligence firm Informa has announced a deal with pharmaceutical reimbursement specialist Real Endpoints (RE) to help biopharma companies improve their understanding of health care plans and payers, and model alternative scenarios.

Informa will use RE's RxScorecard market access tool to extend its range of insights for pharma clients. This tool scores the relative value of competitive marketed and pipeline drugs to support clinical trial design and market access activities, comparing and scoring products on more than 30 metrics covering efficacy, safety and economics. Via a dashboard interface, clients can model rival scenarios based on different assumptions and business goals.

RE, in turn can expand its disease indication coverage and gets access to the resources of 'one of the world's largest pharma and healthcare business intelligence companies'. Real Endpoints CEO Roger Longman says the collaboration 'should give Informa customers a virtual one-stop-shop to support critical development, launch, pricing and access decisions'.

Linda Blackerby, Head of Pharma & Healthcare within Informa's Business Intelligence division, says RxScorecard provides 'an ingenious solution, enabling transparent apples-to-apples drug comparisons'. She comments: 'Tough decisions have to be made throughout the drug development process and RxScorecard will provide our customers with a key intelligence tool to ensure they can maximize their reimbursement potential as they design their trials and approach payers'.

Web sites: www.informa.com and www.realendpoints.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.